After the release of Ophthotech Corp 's fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration.The DisappointmentThe company announced disappointing results from two Phase 3 studies in December, Leerink analysts Joseph Schwartz and Dae Gon Ha said in a note. The studies compared the effectiveness of the drugs Fovista and Lucentis together vs. Lucentis monotherapy.A recent Ophthotech earnings call provided opportunity for the Leerink analysts to learn more about the strategic review plan the company announced earlier this month.via